
AngloGold Ashanti reported a robust Q2 2025, with adjusted EBITDA surging 111% to $1.4 billion and margins expanding to 59%, driven by a 22% increase in H1 gold production, effective cost discipline via its Full Asset Potential Program, and elevated gold prices. The company's stock has soared 144.6% year-to-date, significantly outperforming its industry and broader markets, reflecting strong operational execution. While 2025 sales and earnings are projected for substantial growth, 2026 EPS estimates show a slight decline, indicating a nuanced outlook despite the current strong performance and a forward P/E multiple of 11.41x, which is at a discount to the industry average.
AngloGold Ashanti (AU) has demonstrated exceptional operational performance, reporting a 111% year-over-year increase in adjusted EBITDA to $1.4 billion for Q2 2025, with margins expanding significantly to 59% from 50%. This growth is underpinned by strong fundamentals, including a 22% rise in H1 production to 1.52 million ounces, driven by the Sukari mine acquisition and improved asset output, alongside disciplined cost controls. This combined volume and margin expansion distinguishes AU from peers like Newmont and Agnico Eagle Mines, whose recent EBITDA gains were more heavily reliant on favorable gold prices to offset weaker operational metrics. The market has rewarded this outperformance, with AU's stock surging 144.6% year-to-date. However, forward-looking indicators present a more cautious picture. Despite a discounted forward P/E multiple of 11.41x versus the industry's 12.87x, consensus estimates for 2026 project an earnings decline of 1.3% after a strong 2025. Furthermore, EPS estimates for both 2025 and 2026 have seen negative revisions over the past 60 days, culminating in a Zacks Rank of #4 (Sell), suggesting skepticism about the sustainability of its growth trajectory.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.25
Ticker Sentiment